Therapeutics targeting signal transduction for patients with colorectal carcinoma

British Medical Bulletin

Volumn 64, Issue , 2002, Pages 227-254

  De Bono, Johann S ^a   Rowinsky, Eric K ^a  

^a CTRC Institute for Drug Development   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

6 (4 HYDROXYPHENYL) 4 (ALPHA METHYLBENZYLAMINO) 7H PYRROLO[2,3 D]PYRIMIDINE; CANERTINIB; CELL PROTEIN; CETUXIMAB; CISPLATIN; EPIDERMAL GROWTH FACTOR RECEPTOR; ERLOTINIB; FLUOROURACIL; FOLINIC ACID; GEFITINIB; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; IRINOTECAN; LAPATINIB; MITOGEN ACTIVATED PROTEIN KINASE; PELITINIB; PROTEIN BCL 2; PROTEIN FARNESYLTRANSFERASE INHIBITOR; PROTEIN KINASE B; QUINAZOLINE; RAF PROTEIN; TUMOR NECROSIS FACTOR RELATED APOPTOSIS INDUCING LIGAND;

ACNE; APOPTOSIS; CLINICAL TRIAL; COLORECTAL CARCINOMA; CYTOTOXICITY; DIARRHEA; HUMAN; HYPERSENSITIVITY REACTION; PRIORITY JOURNAL; PROGNOSIS; RASH; REVIEW; SIGNAL TRANSDUCTION; STOMATITIS; THROMBOCYTOPENIA; VOMITING;

ANIMALS; ANTIBODIES, MONOCLONAL; ANTINEOPLASTIC AGENTS; APOPTOSIS; COLORECTAL NEOPLASMS; ENZYME INHIBITORS; GENES, RAS; HUMANS; MAP KINASE SIGNALING SYSTEM; MICE; PROTO-ONCOGENE PROTEINS C-RAF; RANDOMIZED CONTROLLED TRIALS; RECEPTOR, EPIDERMAL GROWTH FACTOR; SIGNAL TRANSDUCTION;

EID: 0036031772     PISSN: 00071420     EISSN: None     Source Type: Journal    
DOI: 10.1093/bmb/64.1.227     Document Type: Review

References (59)

1. Salomon DS, Brandt R, Ciadiello F et al. Epidermal growth factor-related peptides and their receptors in human malignancies. Crit Rev Oncol Hematol 1995; 19: 183-232
2. Mendelsohn J, Baselga J. The EGF receptor family as targets for cancer therapy. Oncogene 2000;19:6550-65
3. Ciardiello F, Tortora G. A novel approach in the treatment of cancer: Targeting the epidermal growth factor receptor. Clin Cancer Res 2001; 7: 2958-70
4. Baselga J. The EGFR as a target for anticancer therapy - Focus on Cetuximab. Eur J Cancer 2001; 37 (Suppl 4): S16-22
5. Baselga J, Pfister D, Cooper MR et al. Phase I studies of anti-epidermal growth factor receptor chimeric antibody C225 alone and in combination with cisplatin. J Clin Oncol 2000; 18: 904-14
6. Shin DM, Donato NJ, Perez-Soler R et al. Epidermal growth factor receptor-targeted therapy with C225 and cisplatin in patients with head and neck cancer. Clin Cancer Res 2001; 7: 1204-13
7. Robert F, Ezekiel MP, Spencer SA et al. Phase I study of anti-epidermal growth factor receptor antibody cetuximab in combination with radiation therapy in patients with advanced head and neck cancer. J Clin Oncol 2001; 19: 3234-43
8. Saltz L, Meropol NJ, Loehrer PJ et al. Single agent IMC-C225 (Erbitux™) has activity in CPT-11-refractory colorectal cancer that expresses the epidermal growth factor receptor (EGFR). Proc Am Soc Clin Oncol 2002; 21: abstract 504
9. Saltz L, Rubin M, Hochster H et al. Cetuximab plus irinotecan is active in CPT-11-refractory colorectal cancer that expresses epidermal growth factor receptor. Proc Am Soc Clin Oncol 2001; 20: abstract 7
10. Rosenberg AH, Loehrer PJ, Needle MN et al. Erbitux (IMC-C225) plus weekly irinotecan (CPT-11), fluorouracil and leucovorin in colorectal cancer that expresses the epidermal growth factor receptor. Proc Am Soc Clin Oncol 2002; 21: abstract 536
11. Yang X et al. Development of ABX-EGF, a fully human anti-EGF receptor monoclonal antibody, for cancer therapy. Crit Rev Oncol Hematol 2001; 38: 17-23
12. Levitt ML, Koty PP. Tyrosine kinase inhibitors in preclinical development. Invest New Drugs 1999; XX: 213-26
13. Woodburn JR. The epidermal growth factor receptor and its inhibition in cancer therapy. Pharmacol Ther 1999; 82: 241-50
14. Arteaga CL, Johnson DH. Tyrosine kinase inhibitors-ZD1839 (Iressa). Curr Opin Oncol 2001; 13: 491-8
15. Roberts RB, Min L, Washington MK et al. Importance of epidermal growth factor receptor signaling in establishment of adenomas and maintenance of carcinomas during intestinal tumorigenesis. Proc Natl Acad Sci USA 2002; 99: 1521-6
16. Ranson M, Hammond LA, Ferry D et al. ZD1839, a selective oral epidermal growth factor receptor-tyrosine kinase inhibitor, is well tolerated and active in patients with solid, malignant tumors: Results of a phase I trial. J Clin Oncol 2002; 20: 2240-50
17. Baselga J, Herbst R, LoRusso P et al. Continuous administration of ZD1839 (Iressa), a novel oral epidermal growth factor receptor tyrosine kinase inhibitor (EGFR-TKI), in patients with five selected tumor types: Evidence of activity and good tolerability. Proc Am Soc Clin Oncol 2000; 19: abstract 177
18. Negoro S, Nakagawa K, Fukuoka M et al. Final results of a phase I intermittent dose-escalation trial of ZD1839 (Iressa) in Japanese patients with various solid tumors. Proc Am Soc Clin Oncol 2001; 20: abstract 1292
19. Goss GD, Hirte H, Lorimer I et al. Final results of the dose escalation phase of a phase I pharmacokinetics, pharmacodynamic and biological activity study of ZD1839: NCIC CTG IND.122. Proc Am Soc Clin Oncol 2001; 20: abstract 335
20. Goss GD, Stewart DJ, Hirte H et al. Initial results of part 2 of a phase I/II pharmacokinetics, pharmacodynamic and biological activity study of ZD1839 (Iressa): NCIC CTG IND.122; Proc Am Soc Clin Oncol 2002; 21: abstract 59
21. de Bono JS, Hammond LA, Figeroa J et al. Phase I/II trial of Iressa™ (ZD1839) in combination with 5-fluorouracil (5-FU) and leucovorin (LV) in patients with metastatic colorectal cancer. Br J Cancer 2002; 87 (Suppl 1): abstract 56
22. Moyer JD, Barbacci EG, Iwata KK et al. Induction of apoptosis and cell cycle arrest by CP-358,774, an inhibitor of epidermal growth factor receptor tyrosine kinase. Cancer Res 1997; 57:4838-48
23. Karp DD et al. Phase I dose escalation study of anti-epidermal growth factor (EGFR) tyrosine kinase (TK) inhibitor CP-358,774 in patients with advanced solid tumors. Proc Am Soc Clin Oncol 1999; 18: abstracts 388 and 1499
24. Hidalgo M et al. Phase I and pharmacologic study of OSI-774, an epidermal growth factor receptor tyrosine kinase inhibitor, in patients with advanced solid malignancies. J Clin Oncol 2001;19:3267-79
25. Hoekstra R, Dumez H, van Oosterom AT. A phase I and pharmacological study of PKI166, an epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor, administered orally in a two weeks on, two weeks off scheme to patients with advanced cancer. Proc Am Soc Clin Oncol 2002; 21: abstract 340
26. Adams VR, Bence KA, Anderson EB et al. A phase I pharmacokinetic/pharmacodynamic study evaluating multiple doses of oral GW572016 in healthy subjects. Proc Am Soc Clin Oncol 2002; 21: abstract 374
27. Fry DW. Inhibition of the epidermal growth factor receptor family of tyrosine kinases as an approach to cancer chemotherapy: Progression from reversible to irreversible inhibitors. Pharmacol Ther 1999; 82: 207-18
28. Erlichman C, Boerner SA, Hallgren V et al. The HER tyrosine kinase inhibitor CI-1033 enhances cytotoxicity of 7-ethyl-10-hydroxycamptothecin and topotecan by inhibiting breast cancer resistance protein-mediated drug efflux. Cancer Res 2001; 61: 739-48
29. Garrison M et al. A phase I and pharmacokinetic study of CI-1033, a pan-ErbB tyrosine kinase inhibitor, given orally on days 1, 8, and 15 every 28 days to patients with solid tumors. Proc Am Soc Clin Oncol 2001; 20: 72a, abstract 283
30. Torrance CJ, Jackson PE, Montgomery E et al. Combinatorial chemoprevention of intestinal neoplasia. Nat Med 2000; 6: 1024-8
31. Hidalgo M, Erlichman C, Rowinsky E et al. Phase 1 trial of EKB-569, an irreversible inhibitor of the epidermal growth factor receptor (EGFR), in patients with advanced solid tumors. Proc Am Soc Clin Oncol 2002; 21: abstract 65
32. Gibbs JB, Oliff A, Kohl NE. Farnesyltransferase inhibitors: Ras research yields a potential cancer therapeutic. Cell 1994; 77: 177-8
33. Rowinsky EK, Windle JJ, Von Hoff DD. Ras protein farnesyltransferase: A strategic target for anticancer drug development. J Clin Oncol 1999; 17: 3631-52
34. Adjei AA. Blocking oncogenic Ras signaling for cancer therapy. J Natl Cancer Inst 2001; 93: 1062-74
35. Johnston SR. Farnesyltransferase inhibitors: A novel targeted therapy for cancer. Lancet Oncol 2001; 2: 18-26
36. End DW, Smets G, Todd AV et al. Characterization of the antitumor effects of the selective farnesyl protein transferase inhibitor R115777 in vivo and in vitro. Cancer Res 2001; 61: 131-7
37. Cunningham D, de Gramont A, Scheithauer W et al. Randomized double-blind placebo-controlled trial of the farnesyltransferase inhibitor R115777 (Zarnestra™) in advanced refractory colorectal cancer. Proc Am Soc Clin Oncol 2002; 21: abstract 502
38. Verslype C, Van Steenbergen W, Humblet Y et al. Phase I trial of 5-FU/LV in combination with the farnesyltransferase inhibitor (FTI) R115777. Proc Am Soc Clin Oncol 2001; 20: abstract 681
39. Weinstein-Oppenheimer CR, Blalock WL, Steelman LS et al. The Raf signal transduction cascade as a target for chemotherapeutic intervention in growth factor-responsive tumors. Pharmacol Ther 2000; 88: 229-79
40. Flaherty KT, Stevenson JP, O'Dwyer PJ. Antisense therapeutics: Lessons from early clinical trials. Curr Opin Oncol 2001; 13: 499-505
41. Workman P, Maloney A. HSP90 as a new therapeutic target for cancer therapy: The story unfolds. Expert Opin Biol Ther 2002; 2: 3-24
42. Lyons JF, Wilhelm S, Hibner B et al. Discovery of a novel Raf kinase inhibitor. Endocr Relat Cancer 2001; 8: 219-25
43. Strumberg D, Bauer RJ, Moeller JG et al. Final results of a phase I pharmacokinetic and pharmacodynamic study of the raf kinase inhibitor BAY 43-9006 in patients with solid tumors Proc Am Soc Clin Oncol 2002; 21: abstract 121
44. Moore M, Hirte H, Oza A et al. Phase I study of the Raf-1 kinase inhibitor BAY 43-9006 in patients with advanced refractory solid tumors. Proc Am Soc Clin Oncol 2002; 21: abstract 1816
45. Pearson G, Robinson F, Beers Gibson T et al. Mitogen-activated protein (MAP) kinase pathways: Regulation and physiological functions. Endocr Rev 2001; 22: 153-83
46. Herrera R, Sebolt-Leopold JS. Unraveling the complexities of the Raf/MAP kinase pathway for pharmacological intervention. Trends Mol Med 2002; 8: S27-31
47. English JM, Cobb MH. Pharmacological inhibitors of MAPK pathways. Trends Pharmacol Sci 2002; 23: 40-5
48. Mitchell DY, Reid JM, Parchment RE et al. Pharmacokinetics (PK) and pharmacodynamics (PD) of the oral MEK inhibitor, CI-1040, following multiple dose administration to patients with advanced cancer. Proc Am Soc Clin Oncol 2002; 21: abstract 320
49. LoRusso PM, Adjei AA, Meyer MB et al. A phase 1 clinical and pharmacokinetic evaluation of the oral MEK inhibitor, CI-1040, administered for 21 consecutive days, repeated every 4 weeks in patients with advanced cancer. Proc Am Soc Clin Oncol 2002; 21: abstract 321
50. Ochoa L, Kuhn J, Salinas R, A phase I, pharmacokinetic, and biologic correlative study of G3139 and irinotecan (CPT-11) in patients with metastatic colorectal cancer. Proc Am Soc Clin Oncol 2001; 20: abstract 297
51. Downward J. Mechanisms and consequences of activation of protein kinase B/Akt. Curr Opin Cell Biol 1998; 10: 262-7
52. Waddick KG, Uckun FM. Innovative treatment programs against cancer: II. Nuclear factor-kappaB (NF-kappaB) as a molecular target. Biochem Pharmacol 1999; 57: 9-17
53. Chang WT, Kang JJ, Lee KY et al. Triptolide and chemotherapy cooperate in tumor cell apoptosis. A role for the p53 pathway. J Biol Chem 2001; 276: 2221-7
54. Adams J. Proteasome inhibition in cancer: Development of PS-341. Semin Oncol 2001; 28: 613-9
55. de Jong S, Timmer T, Heijenbrok FJ, de Vries EG. Death receptor ligands, in particular TRAIL, to overcome drug resistance. Cancer Metastasis Rev 2001; 20: 51-6
56. Betensky RA, Louis DN, Cairncross JG. Influence of unrecognized molecular heterogeneity in randomized clinical trials. J Clin Oncol 2002: 20: 2495-9
57. Stadler WM, Ratain MJ. Development of target-based anti-neoplastic agents. Invest New Drugs 2000; 18: 7-16
58. Freidlin B, Dancey J, Korn EL et al. Multinomial phase II trial designs. J Clin Oncol 2002; 20: 599
59. Von Hoff DD. There are no bad anticancer agents, only bad clinical trial designs: Twenty-first Richard and Hinda Rosenthal Foundation Award Lecture. Clin Cancer Res 1998: 4: 1079-86